Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/01 – EX-4.(J)

On:  Thursday, 6/27/02, at 3:29pm ET   ·   For:  12/31/01   ·   Accession #:  897069-2-485   ·   File #:  1-12033

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report of a Foreign Private Issuer   —   Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report of a Foreign Private Issuer             90    387K 
 2: EX-4.(J)    Research and License Agreement Amendment               3     12K 

EX-4.(J)   —   Research and License Agreement Amendment

EX-4.(J)
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
                                                                    Exhibit 4(j)

RESEARCH AND LICENSE AGREEMENT

 AMENDMENT

THIS AGREEMENT is between RHODE ISLAND HOSPITAL CORPORATION, a    
not-for-profit Rhode Island corporation having offices at 593 Eddy Street,      
Providence, RI 02903 ("RIH") and NYMOX CORPORATION, a corporation having its    
principal place of business at 230 West Passaic Street, Maywood, NJ 07607       
("NYMOX") to amend their existing Research and License Agreement (effective date
March 1, 1999) (the "AGREEMENT") to include the following changes:              

1. The definitions of TECHNOLOGY, LICENSE FIELD, and PRODUCT in the AGREEMENT   
are extended to "research, diagnostic, or therapeutic" by inserting the word    
"research," before the words "diagnostic or therapeutic" in line 3 of the second
WHEREAS in the preamble ("TECHNOLOGY") and in line 2 of paragraph 1.9 ("LICENSE 
FIELD") and by replacing the word "diagnostic" in line 1 of paragraph 1.14      
("PRODUCT") with the phrase "research, diagnostic, or therapeutic."             

2. The definition of FIELD OF RESEARCH in paragraph 1.4 is extended by replacing
the existing paragraph with the following definition:                           

       1.4.   The term "FIELD OF RESEARCH" shall mean research pertaining to the
use of:                                             

         (a) any form of neural thread protein, antibodies or antibody
            variants to neural thread proteins, specific binding or blocking
          molecules to neural thread proteins, and any cDNAs or genes or
genomic fragments coding for neural thread proteins;

      (b) gene transfer technology and transgenic or genetically
    transfected or variants thereof animals or cell lines or
subcellular fractions; and                          

              (c) any form of AF-20 or the AF-20 antigen, antibodies or antibody
       variants to any form of AF-20, specific binding or blocking
              molecules to any form of AF-20 or the AF-20 antigen, and any cDNAs
             or genes or genomic fragments coding for any form of AF-20 or the
AF-20 antigen                                       

      for any purpose including (but not limited to) diagnostic,
therapeutic or research purposes.                   

3. The words "mice or cell lines" in line 2 of paragraph 1.6 (RIH MATERIAL) are 
replaced by the words "animals or cell lines or subcellular fragments."         

EX-4.(J)
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
4. The word "and" in line 3 and line 7 of paragraph 1.7 (INVENTION) is replaced 
by the word "or".                                                               

5. The definition of PATENT RIGHT in paragraph 1.12 is amended by adding a new  
subparagraph (a) and renumbering the other subparagraphs accordingly. The added 
subparagraph is "(a) the United States Patent Application Serial No.            
________________ filed on _____________, 2001 entitled "Inhibition of           
Neurodegeneration"."                                                            

6. The definition of SPONSORED RESEARCH in paragraph 1.18 is amended by         
inserting after the words "EFFECTIVE DATE" the words "and includes scientific   
research performed by an INVESTIGATOR".                                         

7. In accordance with paragraph 2.4(c) of the Agreement, the Research Plan      
appended hereto as Appendix A (the "NEW RESEARCH PROPOSAL") is added to the     
AGREEMENT as a RESEARCH PROPOSAL and replaces the existing RESEARCH PROPOSAL.   
For the purposes of the AGREEMENT, the EFFECTIVE DATE for the part of the NEW   
RESEARCH PROPOSAL entitled "Molecular targeting of human tumors" shall be       
November 1, 2001. Upon the execution of this Amendment, any obligation on the   
part of NYMOX to fund the existing RESEARCH PROPOSAL shall cease and be replaced
by the obligation to fund the NEW RESEARCH PROPOSAL provided for in this        
Amendment.                                                                      

8. NYMOX agrees to support the NEW RESEARCH PROPOSAL with the annual grants in  
accordance with the budget contained in Appendix E as follows:                  

a)     For "Studies on neurodegeneration"                         

         Annual grants of one hundred and seventy-two thousand dollars
         ($172,000) for each of the three (3) years beginning March 1,
           2002, payable on a quarterly basis in the amount of forty-three
              thousand dollars ($43,000) for each of the twelve (12) consecutive
calendar quarters beginning on March 1, 2002.       

b)     For "Molecular targeting of human tumors"                  

              Annual grants of seventy-seven thousand dollars ($77,000) for each
           of the three (3) years beginning November 1, 2001, payable on a
              quarterly basis in the amount of nineteen thousand two hundred and
           fifty dollars ($19,250) for each of the twelve (12) consecutive
calendar quarters beginning on November 1, 2001.    

9. NYMOX hereby requests a license to the United States Patent Application      
Serial No. 09/872,968 filed on June 1, 2001 entitled "Inhibition of             
Neurodegeneration" (the "Patent Application") pursuant to paragraph 6.1 of the  
AGREEMENT and RIH hereby grants NYMOX a license pursuant to the AGREEMENT to the
Patent Application and any PATENT RIGHTS relating to the Patent Application, its
claims and the INVENTIONS disclosed in it.                                      

-2- 

EX-4.(J)
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
IN WITNESS WHEREOF RIH and NYMOX have caused this instrument to be executed.    

NYMOX CORPORATION                        RHODES ISLAND HOSPITAL CORPORATION     

By:   "Paul Averback"                    By:    "Boyd P. King"                  
   ------------------------------           ------------------------------------
Title:   Paul Averback, MD               Title:   Boyd P. King, MD        
CEO and President                        Senior Vice President, Medical   
               Affairs

Date:    11/22/01                        Date:    11/19/01                      
     ----------------------------             ----------------------------------

By:      "Roy Wolvin"                                                           
------------------------------                                            
Title:   Roy Wolvin CFO                                                         

Date:    11/23/01                                                               
----------------------------                                          

I have read the foregoing Amendment and agree to comply with the obligations of 
the Principal Investigator created in consequence of this Amendment to the      
AGREEMENT.                                                                      

By:     "JR Wands"                       By:     "SM de la Monte"               
   ------------------------------           ------------------------------------
Jack Wands, MD                           Suzanne de la Monte, MD          

Date:    "10/30/01"                      Date:    "30 Oct 2001"                 
     ----------------------------             ----------------------------------

-3- 

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘20-F’ Filing		Date		First		Last			Other Filings
Filed on:		6/27/02
		3/1/02		2
For Period End:		12/31/01							20-F/A,  6-K
		11/1/01		2
		6/1/01		2					424B3
		3/1/99		1
									List all Filings

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/02/23  Nymox Pharmaceutical Corp.        20-F       12/31/22  105:5.5M                                   Pubco Reporting … Inc/FA
 3/30/22  Nymox Pharmaceutical Corp.        20-F       12/31/21  106:6M                                     Pubco Reporting … Inc/FA
 3/29/21  Nymox Pharmaceutical Corp.        20-F       12/31/20  103:4.4M                                   Pubco Reporting … Inc/FA